Published in AAPS PharmSci on January 01, 1999
Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther (2005) 0.94
Even low-grade inflammation impacts on small intestinal function. World J Gastroenterol (2010) 0.93
Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. Am J Physiol Gastrointest Liver Physiol (2011) 0.90
Hormonal regulation of dipeptide transporter (PepT1) in Caco-2 cells with normal and anoxia/reoxygenation management. World J Gastroenterol (2003) 0.78
Changes of biological functions of dipeptide transporter (PepT1) and hormonal regulation in severe scald rats. World J Gastroenterol (2003) 0.76
Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology (1989) 5.24
Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem (1995) 2.32
Peptide transporters in the intestine and the kidney. Annu Rev Nutr (1996) 1.81
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun (1996) 1.61
Transepithelial glycylsarcosine transport in intestinal Caco-2 cells mediated by expression of H(+)-coupled carriers at both apical and basal membranes. J Biol Chem (1993) 1.58
Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci (1994) 1.44
Substrate upregulation of the human small intestinal peptide transporter, hPepT1. J Physiol (1998) 1.33
An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res (1998) 1.05
Localization of peptide transporter in nuclei and lysosomes of the pancreas. Int J Pancreatol (1997) 0.95
Gut epithelial cells as targets for gene therapy of hemophilia. Hum Gene Ther (1997) 0.93
Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of beta-lactam antibiotics. FEBS Lett (1996) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Development and utility of anti-PepT1 anti-peptide polyclonal antibodies. Pharm Res (1998) 0.79
HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet (1992) 2.93
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med (1995) 2.04
Silk fibroin as an organic polymer for controlled drug delivery. J Control Release (2006) 1.71
Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem (1988) 1.69
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol (1993) 1.63
Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med (1995) 1.58
Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim (2001) 1.54
Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol (1995) 1.47
The Venus flytrap of periplasmic binding proteins: an ancient protein module present in multiple drug receptors. AAPS PharmSci (1999) 1.47
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis (1999) 1.45
Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release (2001) 1.45
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol (1998) 1.44
Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. J Pediatr (1993) 1.41
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
Silk based biomaterials to heal critical sized femur defects. Bone (2006) 1.40
Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem (2003) 1.39
Images in cardiovascular medicine. Idiopathic hypereosinophilic vasculitis. Circulation (1995) 1.39
Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol (2009) 1.39
Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. Genes Immun (2005) 1.37
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. J Biol Chem (2001) 1.30
Effect of scaffold design on bone morphology in vitro. Tissue Eng (2006) 1.28
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
BMP-silk composite matrices heal critically sized femoral defects. Bone (2007) 1.22
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis (1980) 1.22
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther (1998) 1.19
Dynamics of tight and adherens junctions under EGTA treatment. J Membr Biol (2002) 1.17
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Equilibration and exchange of fluorescently labeled molecules in skinned skeletal muscle fibers visualized by confocal microscopy. Biophys J (1995) 1.16
Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. J Control Release (1999) 1.16
Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol (2001) 1.15
Spot-blot hybridization assay for the detection of hepatitis B virus DNA in serum: factors determining its sensitivity and specificity. Hepatology (1987) 1.15
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Interfacial adsorption and aggregation associated changes in secondary structure of human calcitonin monitored by ATR-FTIR spectroscopy. Biochemistry (1994) 1.10
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol (1990) 1.09
Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology (1988) 1.09
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb Haemost (1979) 1.08
Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology (1991) 1.08
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J (1993) 1.07
HIV-1 infected women and prenatal care utilization: barriers and facilitators. AIDS Patient Care STDS (2000) 1.06
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos (2003) 1.03
Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem (2001) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine (1995) 1.02
Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol (1981) 1.02
Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release (2001) 1.01
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC. Eur J Biochem (2000) 0.99
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
Importance of the test medium for the release kinetics of a somatostatin analogue from poly(D,L-lactide-co-glycolide) microspheres. Int J Pharm (1999) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry (1998) 0.98
Cell cultures as tools in biopharmacy. Eur J Pharm Sci (2000) 0.97
MDCK cell cultures as an epithelial in vitro model: cytoskeleton and tight junctions as indicators for the definition of age-related stages by confocal microscopy. Pharm Res (1998) 0.97
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Penicillin-induced coagulation disorder. Lancet (1976) 0.96
Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J Pharm Sci (2000) 0.95
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides. Biochim Biophys Acta (2003) 0.95
Surface modification of PLGA microspheres. J Biomed Mater Res A (2003) 0.95